https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-vk2735-obesity-week-2026 BiopharmaWatch en 2026-11-15T17:05:00.000Z Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026 https://www.biopharmawatch.com/news/HELP/helus-pharma-phase-3-approach-study-results BiopharmaWatch en 2026-11-15T17:00:00.000Z Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026 https://www.biopharmawatch.com/news/CVS/cvs-health-glp-1-benefits-affordability-challenge BiopharmaWatch en 2026-11-15T15:00:00.000Z CVS Health study highlights GLP-1 benefits and the affordability challenge https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-15T12:00:00.000Z Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026 https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-ivonescimab-update BiopharmaWatch en 2026-11-15T12:00:00.000Z Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-business-update-q3-2026 BiopharmaWatch en 2026-11-15T12:00:00.000Z Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/LLY/lilly-obesityweek-2026-data-presentation BiopharmaWatch en 2026-11-14T17:01:00.000Z Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale https://www.biopharmawatch.com/news/AMLX/amylyx-avexitide-phase-3-results-obesityweek-2026 BiopharmaWatch en 2026-11-14T17:00:00.000Z Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting https://www.biopharmawatch.com/news/WWB/windward-bio-nasdaq-ipo BiopharmaWatch en 2026-11-14T15:57:00.000Z Innovative Immunology Biotech Windward Bio Lists on Nasdaq https://www.biopharmawatch.com/news/ZLAB/zai-lab-2026-nrdl-inclusion-karxt-vyvgart BiopharmaWatch en 2026-11-14T03:26:00.000Z Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products https://www.biopharmawatch.com/news/VVVV/nyse-welcomes-vvardis-publicly-listed-company BiopharmaWatch en 2026-11-13T22:56:00.000Z The NYSE Welcomes vVARDIS as a Publicly Listed Company https://www.biopharmawatch.com/news/CNSY/cerenome-q3-2026-results-reyobiq-progress BiopharmaWatch en 2026-11-13T22:19:00.000Z Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress https://www.biopharmawatch.com/news/BYSI/beyondspring-third-quarter-2026-results-update BiopharmaWatch en 2026-11-13T22:15:00.000Z BeyondSpring Reports Third-Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/IMCC/im-cannabis-corp-q3-2026-financial-results BiopharmaWatch en 2026-11-13T22:10:00.000Z IM Cannabis Corp. Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ARAY/accuray-tcw-transaction-strengthening-balance-sheet BiopharmaWatch en 2026-11-13T22:10:00.000Z Accuray Closes TCW Transaction, Strengthening Balance Sheet to Support Long-Term Value Growth https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-q3-2026-results BiopharmaWatch en 2026-11-13T22:03:00.000Z Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/TPST/tempest-reports-q3-2026-results-business-update BiopharmaWatch en 2026-11-13T21:47:00.000Z Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/CING/cingulate-reports-q3-2026-results-ctx-1301-update BiopharmaWatch en 2026-11-13T21:45:00.000Z Cingulate Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA Resubmission https://www.biopharmawatch.com/news/ZLAB/zai-lab-investor-conferences-november-2026 BiopharmaWatch en 2026-11-13T21:35:00.000Z Zai Lab Announces Participation in Investor Conferences in November 2026 https://www.biopharmawatch.com/news/TMO/thermo-fisher-scientific-ubs-ceo-call-2026 BiopharmaWatch en 2026-11-13T21:30:00.000Z Thermo Fisher Scientific to Participate in UBS 2026 CEO Call Series on November 19, 2026 https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-fiscal-2027-q1-results BiopharmaWatch en 2026-11-13T21:30:00.000Z Natural Alternatives International, Inc. Announces Fiscal 2027 Q1 Results https://www.biopharmawatch.com/news/ASTC/astrotech-fiscal-year-2027-financial-results BiopharmaWatch en 2026-11-13T21:20:29.000Z ASTROTECH REPORTS FIRST QUARTER OF FISCAL YEAR 2027 FINANCIAL RESULTS https://www.biopharmawatch.com/news/MEDS/datameds-ai-reports-revenue-growth-q3-2026 BiopharmaWatch en 2026-11-13T21:15:45.000Z DataMEDS AI Reports 50% Sequential Revenue Growth in Third Quarter 2026 From Second Quarter 2026, Delivers Net Profit Per Share of $2.72 and Provides Business Update https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-new-employee-inducement-grants-nasdaq-listing-rule-20261113 BiopharmaWatch en 2026-11-13T21:15:00.000Z Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/EOLS/evolus-reports-inducement-grants-nasdaq-listing-rule-5635-c-4 BiopharmaWatch en 2026-11-13T21:05:00.000Z Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/GH/guardant-health-announces-inducement-grants-nasdaq-listing-rule-5635-c BiopharmaWatch en 2026-11-13T21:05:00.000Z Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-q3-2026-financial-results BiopharmaWatch en 2026-11-13T21:05:00.000Z Enveric Biosciences Reports Financial Results for Third Quarter 2026 and Provides Corporate Update https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-q3-2026-financial-results BiopharmaWatch en 2026-11-13T21:05:00.000Z TherapeuticsMD Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/FEMY/femasys-financial-results-q3-2026-update BiopharmaWatch en 2026-11-13T21:05:00.000Z Femasys Announces Financial Results for Quarter Ended September 30, 2026 and Provides Corporate Update https://www.biopharmawatch.com/news/FDMT/4dmt-announces-new-employment-inducement-grants-20261113 BiopharmaWatch en 2026-11-13T21:05:00.000Z 4DMT Announces New Employment Inducement Grants https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-13T21:05:00.000Z Indaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/VTGN/vistagen-fiscal-year-2027-q2-results-update BiopharmaWatch en 2026-11-13T21:05:00.000Z Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/KRRO/korro-bio-stock-option-grant-nasdaq-rule-5635 BiopharmaWatch en 2026-11-13T21:05:00.000Z Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/OCS/oculis-notifications-transactions-managerial-responsibilities BiopharmaWatch en 2026-11-13T21:05:00.000Z Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities https://www.biopharmawatch.com/news/INBX/inhibrx-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-13T21:02:00.000Z Inhibrx Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TRXB/trexbio-reports-q3-2026-results-business-highlights BiopharmaWatch en 2026-11-13T21:02:00.000Z TRexBio Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/NVS/novartis-cosentyx-chmp-opinion-hidradenitis-suppurativa BiopharmaWatch en 2026-11-13T18:30:00.000Z Novartis receives positive CHMP opinion for Cosentyx® in adolescents aged 12+ with hidradenitis suppurativa (HS)